Dear Editor,Recombinant protein therapeutics and gene therapies can help rescue monogenic disease phenotypes(Ebrahimi and Samanta,2023).Sufficient/high expression of a therapeutic product is an important consideration...Dear Editor,Recombinant protein therapeutics and gene therapies can help rescue monogenic disease phenotypes(Ebrahimi and Samanta,2023).Sufficient/high expression of a therapeutic product is an important consideration in this regard,which is usually achieved by gene redesign,focused on altering synonymous codon usage/codon context,aimed at enhancing translational rates(Alexaki et al.,2019).Different approaches exist to adjust synonymous codon usage and boost protein expression levels(Katneni et al.,2022).As these strategies do not alter the primary sequence of a protein(Liu et al.,2021)they are not expected to alter protein structure and function.However。展开更多
基金supported by grant R01HL151392(to A.A.K)and AMED-CREST with Grant Number JP21gm1410008(to H.T.)supported by funds from the Center for Biologics Evaluation and Research,US Food and Drug Administration.
文摘Dear Editor,Recombinant protein therapeutics and gene therapies can help rescue monogenic disease phenotypes(Ebrahimi and Samanta,2023).Sufficient/high expression of a therapeutic product is an important consideration in this regard,which is usually achieved by gene redesign,focused on altering synonymous codon usage/codon context,aimed at enhancing translational rates(Alexaki et al.,2019).Different approaches exist to adjust synonymous codon usage and boost protein expression levels(Katneni et al.,2022).As these strategies do not alter the primary sequence of a protein(Liu et al.,2021)they are not expected to alter protein structure and function.However。
